ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / EDIT / financials
ALLO (33) CCCC (29) AUTL (21) PROK (35) ⌘ Pro Terminal →

Editas Medicine Inc. (EDIT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$2.57 -3.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.55

Editas Medicine Inc. (EDIT) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $410.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EDIT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Editas Medicine Inc. (NASDAQ: EDIT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.57 (-3.74% 1D, market cap $410.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EDIT ranks #828 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EDIT compare to ALLO and CCCC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALLO (Allogene Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $407.7M) and CCCC (C4 Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $414.6M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EDIT?
▼

Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.55 (-0.86%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (6)Whales (8)SEC (8)Macro (4)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.2% Base Target
$4 Bull$2 Base$2 Bear
📬 FREE EDIT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EDIT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY EDIT SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
21
Grade E$2.44+5.7% Next Q
Q2 (-2Q)
24
Grade E$2.58+0.8% Next Q
Q3 (-1Q)
26
Grade E$2.60-1.2% Next Q
Current
29
Grade E$2.57-9.8% Hist 90D α
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EDIT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EDIT currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.75) and Max Pain ($2.70) forces dealer call-delta covering toward $4.14.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EDIT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EDIT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How EDIT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$40.5MGross Profit $21.1M (52%)Cost of Sales $19.4MOp Profit $0 (0%)OpEx (R&D/SG&A) $21.1MNet Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow
FY23
Rev $78.1M
FY24
Rev $32.3M
FY25
Rev $40.5M
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$40.5M52%-80%-$160.1M-$165.8M-45%
FY 2024$32.3M52%-80%-$237.1M-$219.1M-45%
FY 2023$78.1M52%-80%-$153.2M-$132.2M-35%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EDIT)

  • ✓Walkthrough of EDIT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
EDIT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -14.33%▼ DESCENDING CHANNEL
2026-11-03O $2.93H $2.93L $2.57C $2.57VOL 2.91M
RES: $2.94SUP: $2.17SMA50: $2.75SMA200: $2.69
$4.06$3.57$3.07$2.58$2.09RES $2.94SUP $2.17$2.572026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EDIT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EDIT Butterfly Map → + Track EDIT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EDIT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EDIT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EDIT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EDIT)

Health Care Rank #828 of 1015 ⚔️ ALLO vs EDIT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EDIT vs. ALLO, CCCC, AUTL, PROK)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Editas Medicine Inc. (EDIT) ranks #828 by composite RQD confidence (29/100, grade E) and #468 by equity capitalization ($410.1M). Within this direct 5-issuer industry benchmark cohort, EDIT leads on earnings valuation at N/A trailing P/E, while EDIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PROK currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with EDIT at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
EDIT ACTIVE
Editas Medicine Inc.
E 29/100 — — -35.0% -3.74% $410.1M Benchmark Subject
ALLO
Allogene Therapeutics Inc.
E 33/100 — — -35.0% -7.63% $407.7M /allo-vs-edit →
CCCC
C4 Therapeutics Inc.
E 29/100 — — -35.0% -4.75% $414.6M /cccc-vs-edit →
AUTL
Autolus Therapeutics plc
E 21/100 — -27.8% -35.0% -6.58% $404.6M /autl-vs-edit →
PROK
ProKidney Corp. (Class A)
D- 35/100 — — -35.0% -13.51% $391.6M /prok-vs-edit →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001650664 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Editas Medicine Inc. (EDIT) reported GAAP revenue of $40.5M (+25.4% vs. FY2024 revenue of $32.3M , and -48.1% cumulative change since FY2023) , GAAP net income of -$160.1M, operating cash flow of -$165.2M, and free cash flow of -$165.8M (+24.3% YoY). On the balance sheet, EDIT closed FY2025 with $186.5M in total assets against $53.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $40.5M -$160.1M -$165.2M -$165.8M $186.5M $53.6M
FY2024 (FY) 2024-12-31 $32.3M -$237.1M -$210.3M -$219.1M $341.6M $52.4M
FY2023 (FY) 2023-12-31 $78.1M -$153.2M -$132.2M -$132.2M — —

3. EDIT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Editas Medicine Inc. (NASDAQ: EDIT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.57 (-3.74% 1D, market cap $410.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 4/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, EDIT ranks #828 in composite RQD confidence.

How does EDIT compare to ALLO and CCCC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALLO (Allogene Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $407.7M) and CCCC (C4 Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $414.6M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for EDIT?

Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is EDIT trading relative to its 50-day, 200-day, and 52-week technical levels?

EDIT last traded at $2.57 (-3.74% on volume of 1,236,887 shares), positioning the stock -6.55% below its 50-day simple moving average ($2.75) and -4.46% below its 200-day simple moving average ($2.69). Across its 52-week range of $1.66 to $3.94, EDIT sits at the 39.9% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.25 to $2.89).

Direct Sub-Reports: EDIT RQD Cockpit EDIT 12M Forecast EDIT Earnings & Move EDIT Dividends & DRIP EDIT Insiders & 13F EDIT Whale Options EDIT Profit Sankey EDIT News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

EDIT — Editas Medicine Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Editas Medicine Inc. (EDIT) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.57 (-3.74% 1D, market capitalization $410.1M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (4/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of 1.96x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Editas Medicine Inc. (EDIT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company has a market capitalization of $0.4B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Editas Medicine Inc. (EDIT) reported $40.5M in annual revenue (up from $32.3M in FY2024, +25.4% YoY) and -$160.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($78.1M revenue, -$153.2M net income) through FY2025, EDIT scaled operating cash flow to -$165.2M and free cash flow to -$165.8M, backed by $186.5M in total assets against $53.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $1.66 – $3.94 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), EDIT carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can EDIT sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $40.5M and free cash flow of -$165.8M, how will capital allocation balance growth reinvestment against $53.6M in total debt?
  • Key Question #3: How sensitive is EDIT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EDIT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Editas Medicine Inc. (EDIT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EDIT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EDIT Bull vs. Bear Conversation Board — What's Your Call at $2.57?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EDIT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on EDIT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $3.39 (+27.0%)
📌 Pinned Debate

Per the news wire, Australia cleared a Phase 1/2 trial of EDIT-401 and shares rose on the news.

Per the news wire, Australia cleared a Phase 1/2 trial of EDIT-401 and shares rose on the news.. When you look under the hood at EDIT, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $3.94. My 12M target is $3.39.

ArenaChamp_24 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $2.30 (-13.9%)
Spot @ $2.67

Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%, with the Piotroski F-Score at 3/9 and Debt/Equity at 1.96.

Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%, with the Piotroski F-Score at 3/9 and Debt/Equity at 1.96.. Look at the math on EDIT: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $2.35 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%